ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Holdings Decreased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,291 shares of the specialty pharmaceutical company’s stock after selling 207 shares during the period. The Manufacturers Life Insurance Company’s holdings in ANI Pharmaceuticals were worth $554,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Innealta Capital LLC acquired a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $65,000. Ridgewood Investments LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $85,000. XTX Topco Ltd acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $207,000. Profund Advisors LLC bought a new position in ANI Pharmaceuticals during the second quarter worth $225,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in ANI Pharmaceuticals in the second quarter worth $228,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on ANIP. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday. They set an “outperform” rating and a $80.00 target price for the company. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $56.59 on Friday. The firm’s 50 day moving average is $58.01 and its two-hundred day moving average is $60.31. The firm has a market capitalization of $1.19 billion, a P/E ratio of -102.89 and a beta of 0.73. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52 week low of $51.79 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s revenue was up 12.5% compared to the same quarter last year. During the same period last year, the firm earned $1.05 EPS. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Insider Activity

In related news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This trade represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,731 shares of company stock valued at $2,015,861. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.